Der Internist

, Volume 52, Issue 12, pp 1407–1413 | Cite as

Therapiemanagement bei Malaria

Schwerpunkt

Zusammenfassung

Eine Malaria tropica – seltener die anderen Malariaformen – kann rasch zu zerebralen, renalen oder pulmonalen Komplikationen und zu lebensbedrohlichen Verläufen führen. Die Letalität bei schwerer Malaria liegt bei etwa 10%. Bei Fieber nach Tropenaufenthalt muss daher immer differenzialdiagnostisch an eine Malaria gedacht werden. Werden Plasmodien nachgewiesen, muss die Therapie rasch einsetzen – bei schweren Verlaufsformen mit Chinin oder Artesunat. Krankenhäuser sollten ihr Vorgehen bei Patienten mit Malariaverdacht bzw. bei nachgewiesener Malaria in einer Standard Operating Procedure festlegen.

Schlüsselwörter

Malaria tropica Malariatherapie Plasmodien Chinin Artesunat 

Therapeutic management of malaria

Abstract

Plasmodium falciparum and to some extent malaria caused by other species of Plasmodia can quickly lead to cerebral malaria, acute renal failure, or acute respiratory distress syndrome. The mortality rate for patients with severe malaria lies around 10%. Malaria must be given priority in the differential diagnosis of travelers returning febrile from endemic areas. Treatment requires prompt administration of safe and fast-acting antimalarials, which in severe malaria is treatment with quinine or artesunate. Hospitals must be prepared to diagnose and treat malaria patients—or have a standard operating procedure for transferring the patient to a specialized center.

Keywords

Falciparum malaria Malaria therapy Plasmodia Quinine Artesunate 

Literatur

  1. 1.
    Bruneel F, Tubach F, Corne P et al; Severe Imported Malaria in Adults (SIMA) Study Group (2010) Severe imported falciparum malaria: a cohort study in 400 critically ill adults. PLoS One 5:e13236PubMedCrossRefGoogle Scholar
  2. 2.
    Cramer JP, Lopez-Velez R, Burchard GD et al (2011) Treatment of imported severe malaria with artesunate instead of quinine – more evidence needed? Malar J 10:256PubMedCrossRefGoogle Scholar
  3. 3.
    Dondorp A, Nosten F, Stepniewska K et al (2005) Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366:717–725PubMedCrossRefGoogle Scholar
  4. 4.
    Dondorp AM, Fairhurst RM, Slutsker L et al (2011) The threat of artemisinin-resistant malaria. N Engl J Med 365:1073–1075PubMedCrossRefGoogle Scholar
  5. 5.
    Dondorp AM, Fanello CI, Hendriksen IC et al (2010) Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 376:1647–1657PubMedCrossRefGoogle Scholar
  6. 6.
    Dorovini-Zis K, Schmidt K, Huynh H et al (2011) The neuropathology of fatal cerebral malaria in malawian children. Am J Pathol 178:2146–2158PubMedCrossRefGoogle Scholar
  7. 7.
    Efferth T, Kaina B (2010) Toxicity of the antimalarial artemisinin and its derivatives. Crit Rev Toxicol 40:405–421PubMedCrossRefGoogle Scholar
  8. 8.
    Hanson J, Uddin Hasan MM et al (2011) Laboratory prediction of the requirement for renal replacement in acute falciparum malaria. Malar J 10:217PubMedCrossRefGoogle Scholar
  9. 9.
    Idro R, Marsh K, John CC, Newton CR (2010) Cerebral malaria: mechanisms of brain injury and strategies for improved neurocognitive outcome. Pediatr Res 68:267–274PubMedCrossRefGoogle Scholar
  10. 10.
    Kantele A, Jokiranta TS (2011) Review of cases with the emerging fifth human malaria parasite, Plasmodium knowlesi. Clin Infect Dis 52:1356–1362PubMedCrossRefGoogle Scholar
  11. 11.
    Leder K, Tong S, Weld L et al (2006) GeoSentinel Surveillance Network. Illness in travelers visiting friends and relatives: a review of the GeoSentinel Surveillance Network. Clin Infect Dis 43:1185–1193PubMedCrossRefGoogle Scholar
  12. 12.
    Li A, Lim TS, Shi H et al (2011) Molecular mechanistic insights into the endothelial receptor mediated cytoadherence of Plasmodium falciparum-infected erythrocytes. PLoS One 6:e16929PubMedCrossRefGoogle Scholar
  13. 13.
    Medana IM, Day NP, Sachanonta N et al (2011) Coma in fatal adult malaria is not caused by cerebral oedema. Malar J 10:267PubMedCrossRefGoogle Scholar
  14. 14.
    Mohanty S, Mishra SK, Patnaik R et al (2011) Brain swelling and mannitol therapy in adult cerebral malaria: a randomized trial. Clin Infect Dis 53:349–355PubMedCrossRefGoogle Scholar
  15. 15.
    Odolini S, Parola P, Gkrania-Klotsas E et al (2011) Travel-related imported infections in Europe, EuroTravNet 2009. Clin Microbiol Infect doi: 10.1111/j.1469-0691.2011.03596.x [Epub ahead of print]Google Scholar
  16. 16.
    Püschel K, Lockemann, U, Dietrich M (1998) Malaria – Immer wieder Todesfälle infolge verspäteter Diagnose. Dtsch Arztebl 95:A-2697–2700Google Scholar
  17. 17.
    Rayner JC, Liu W, Peeters M et al (2011) A plethora of Plasmodium species in wild apes: a source of human infection? Trends Parasitol 27:222–229PubMedCrossRefGoogle Scholar
  18. 18.
    Sarkar PK, Ahluwalia G, Vijayan VK, Talwar A (2010) Critical care aspects of malaria. J Intensive Care Med 25:93–103PubMedCrossRefGoogle Scholar
  19. 19.
    World Health Organization (2010) Guidelines for the treatment of malaria, second edition. WHO, Genf, ISBN: 9789241547925Google Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Sektion Tropenmedizin/Infektiologie, I. Medizinische KlinikUniversitätsklinikum Hamburg-EppendorfHamburgDeutschland

Personalised recommendations